Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022
暂无分享,去创建一个
M. Ajelli | Juanjuan Zhang | Xinhua Chen | K. Sun | J. Cai | Hongjie Yu | Jiaxin Zhou | N. Zheng | R. Sun | Xuemei Yan | X. Deng | T. Zhuang
[1] Xiang Guo,et al. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death , 2022, BMC Medicine.
[2] E. Lau,et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study , 2022, The Lancet Infectious Diseases.
[3] M. Lipsitch,et al. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California , 2022, Nature Medicine.
[4] M. Ajelli,et al. Modeling transmission of SARS-CoV-2 Omicron in China , 2022, Nature Medicine.
[5] Wenhong Zhang,et al. Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic , 2022, The Lancet.
[6] E. Lau,et al. Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January–March 2022 , 2022, medRxiv.
[7] R. Milo,et al. Estimating disease severity of Omicron and Delta SARS-CoV-2 infections , 2022, Nature Reviews Immunology.
[8] Ryan T Novak,et al. COVID-19 Mortality and Vaccine Coverage — Hong Kong Special Administrative Region, China, January 6, 2022–March 21, 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[9] D. He,et al. Reduction in the infection fatality rate of Omicron variant compared with previous variants in South Africa , 2022, International Journal of Infectious Diseases.
[10] E. Lau,et al. Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong , 2022, medRxiv.
[11] M. Exline,et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study , 2022, BMJ.
[12] C. Viboud,et al. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21 , 2022, The Lancet Infectious Diseases.
[13] S. Madhi,et al. Population Immunity and Covid-19 Severity with Omicron Variant in South Africa. , 2022, The New England journal of medicine.
[14] Georgia Salanti,et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis , 2020, medRxiv.
[15] S. Merler,et al. Probability of symptoms and critical disease after SARS-CoV-2 infection , 2020, 2006.08471.
[16] Simon Cauchemez,et al. Assessing the severity of the novel influenza A/H1N1 pandemic , 2009, BMJ : British Medical Journal.